VALEANT PHARMACEUTICALS INTERNATIONAL TO ACQUIRE BAUSCH + LOMB FOR $8.7 BILLION

VALEANT PHARMACEUTICALS INTERNATIONAL TO ACQUIRE BAUSCH + LOMB FOR $8.7 BILLION

Valeant Pharmaceuticals International and Bausch + Lomb Holdings Incorporated have entered into a definitive agreement under which Valeant will acquire Bausch + Lomb for $8.7 billion in cash. Under the terms of the agreement, Valeant will pay $ 8.7 billion in cash, of which approximately $4.5 billion will go to an investor group led by Warburg Pincus and approximately $4.2 billion will be used to repay Bausch + Lomb's outstanding debt. Bausch + Lomb will retain its name and become a division of Valeant. Valeant's existing ophthalmology businesses will be integrated into the Bausch + Lomb division. www.bausch.com

Latest Articles

Towards a Unified IOL Classification

The new IOL functional classification needs a strong and unified effort from surgeons, societies, and industry.

The 5 Ws of Post-Presbyopic IOL Enhancement

Fine-tuning refractive outcomes to meet patient expectations.

AI Shows Promise for Meibography Grading

Study demonstrates accuracy in detecting abnormalities and subtle changes in meibomian glands.

Are There Differences Between Male and Female Eyes?

TOGA Session panel underlined the need for more studies on gender differences.

Simulating Laser Vision Correction Outcomes

Individualised planning models could reduce ectasia risk and improve outcomes.

Mastering IOL Exchange

Tips and tricks for an uncomplicated replacement procedure.

Need to Know: Aberrations, Aberrometry, and Aberropia

Understanding the nomenclature and techniques.

When Is It Time to Remove a Phakic IOL?

Close monitoring of endothelial cell loss in phakic IOL patients and timely explantation may avoid surgical complications.

Delivering Uncompromising Cataract Care

Expert panel considers tips and tricks for cataracts and compromised corneas.

Organising for Success

Professional and personal goals drive practice ownership and operational choices.